Nanotechnologies for the delivery of biologicals: historical perspective and current landscape

dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicasgl
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéuticagl
dc.contributor.authorDurán-Lobato, Matilde
dc.contributor.authorLópez Estévez, Ana María
dc.contributor.authorCordeiro, Ana Sara
dc.contributor.authorGómez Dacoba, Tamara
dc.contributor.authorCrecente Campo, José
dc.contributor.authorTorres López, Dolores
dc.contributor.authorAlonso Fernández, María José
dc.date.accessioned2022-03-21T08:47:06Z
dc.date.available2022-03-21T08:47:06Z
dc.date.issued2021
dc.description.abstractBiological macromolecule-based therapeutics irrupted in the pharmaceutical scene generating a great hope due to their outstanding specificity and potency. However, given their susceptibility to degradation and limited capacity to overcome biological barriers new delivery technologies had to be developed for them to reach their targets. This review aims at analyzing the historical seminal advances that shaped the development of the protein/peptide delivery field, along with the emerging technologies on the lead of the current landscape. Particularly, focus is made on technologies with a potential for transmucosal systemic delivery of protein/peptide drugs, followed by approaches for the delivery of antigens as new vaccination strategies, and formulations of biological drugs in oncology, with special emphasis on mAbs. Finally, a discussion of the key challenges the field is facing, along with an overview of prospective advances are providedgl
dc.description.peerreviewedSIgl
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Science, Innovation and Universities (Ref.SAF2017-86634-R), the government of Xunta de Galicia (Competitive Reference Groups, Ref:ED431C2017/09), and MINECO- PCIN-2017-129/ AEI, under the frame of EuroNanoMed III. M. Durán-Lobato acknowledges a postdoctoral contract granted by “VI Plan Propio” from the University of Seville (grant number USE-19533-Y), and Ana M. López-Estévez acknowledges a predoctoral FPU grant from the Spanish Ministry of Science, Innovation and Universities (grant number FPU18/00095)gl
dc.identifier.citationAdvanced Drug Delivery Reviews 176 (2021) 113899. https://doi.org/10.1016/j.addr.2021.113899gl
dc.identifier.doi10.1016/j.addr.2021.113899
dc.identifier.essn0169-409X
dc.identifier.urihttp://hdl.handle.net/10347/27687
dc.language.isoenggl
dc.publisherElseviergl
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/SAF2017-86634-R/ES/NANO-INMUNOTERAPIAS INTEGRADAS DIRIGIDAS A DIANAS INTRACELULARES RELEVANTES EN CANCERgl
dc.relation.publisherversionhttps://doi.org/10.1016/j.addr.2021.113899gl
dc.rights©2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)gl
dc.rights.accessRightsopen accessgl
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectDrug deliverygl
dc.subjectProtein deliverygl
dc.subjectPeptide deliverygl
dc.subjectmAbsgl
dc.subjectTransmucosalgl
dc.subjectOralgl
dc.subjectNasalgl
dc.subjectVaccinegl
dc.subjectOncologicalsgl
dc.titleNanotechnologies for the delivery of biologicals: historical perspective and current landscapegl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublication0eba3b8f-1519-454b-93c0-f390922d4645
relation.isAuthorOfPublication7bcdc357-e1b8-4198-b799-86057649f479
relation.isAuthorOfPublication.latestForDiscovery7bcdc357-e1b8-4198-b799-86057649f479

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021_addrev_duran_nanotechnologies.pdf
Size:
4.38 MB
Format:
Adobe Portable Document Format
Description:
Artigo de investigación